27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Gainers
Vascular Biogenics Ltd (NASDAQ: VBLT) shares rose 35.01 percent to $5.36 in pre-market trading following positive VB-111 data.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Exelixis, Inc. (NASDAQ: EXEL) rose 8.50 percent to $7.15 in pre-market trading. Exelixis and its partner Ipsen (OTC: IPSEY) reported positive positive overall survival results from subgroup analyses of Phase 3 trial of CABOMETYX tablets in advanced renal cell carcinoma.
Xcerra Corp (NASDAQ: XCRA) shares rose 6.57 percent to $7.46 in pre-market trading. Xcerra reported Q3 earnings of $0.00 per share on revenue of $82.237 million.
Eleven Biotherapeutics Inc (NASDAQ: EBIO) shares rose 6.05 percent to $2.28 in pre-market trading after surging 20.79 percent on Friday.
Array Biopharma Inc (NASDAQ: ARRY) rose 3.43 percent to $3.92 in pre-market trading. Array BioPharma, Pierre Fabre and Merck KGaA reported Phase 3 BEACON CRC trial.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
ProNAi Therapeutics Inc (NASDAQ: DNAI) shares 60.82 percent to $2.50 in pre-market trading after the company reports interim data from Wolverine Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL). The company discontinued the development of DLBCL.
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) fell 45.94 percent to $4.79 in pre-market trading as the company revealed Monday it was advised by the FDA to expand its human study, as well as reliability student, i.e. product stress testing, to get its support for its NDA for Epinephrine injection. The medical regulator issued a complete response letter to it on Friday after the market closed.
Ocular Therapeutix Inc (NASDAQ: OCUL) shares fell 32.49 percent to $8.00 in pre-market trading after the company reported Phase 3 clinical trial of DEXTENZA for allergic conjunctivitis. The trail did not meet primary endpoint.
Lion Biotechnologies Inc (NASDAQ: LBIO) shares fell 5.43 percent to $8.18 in pre-market trading after surging 43.45 percent on Friday.
AbbVie Inc (NYSE: ABBV) shares fell 3.68 percent to $62.64. AbbVie presented Phase 1 data for ABT-414. Cowen & Company downgraded AbbVie from Outperform to Market Perform.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.